Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Name: Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
Published: 2026
License: Public Domain

Beijing Biotech · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

recurrent or metastatic esophageal adenocarcinoma, biomarker-selected cldn18.2-positive and/or her2-positive disease, car-nk, allogeneic nk cells, cellular immunotherapy, cldn18.2, her2 (erbb2), egfr (exploratory biomarker), esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma, dose escalation, dose expansion

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 872295
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.